Influence of erythropoietin dose and albumin level on the plasma brain natriuretic peptide in hemodialysis patients

Abstract EN

Brain natriuretic peptide (BNP) levels increase in patients with congestive heart failure.

Theoretically, BNP levels can be helpful in the determination of the "dry weight" of hemodialysis patients.

To evaluate the effect of hemodialysis on the plasma concentration of BNP and to determine the factors that affect BNP levels during hemodialysis in patients with chronic renal failure, we studied five stable patients with chronic renal failure.

A total of 15 blood samples were obtained for BNP levels at 24, 48 and 72 hours after the last hemodialysis session.

The plasma BNP levels did not change significantly either with ultrafiltration volume or with time since last dialysis.

However, the BNP levels correlated positively with the erythropoietin (EPO) dose (r = 0.98, P < 0.001) and negatively with the serum albumin levels (r = 0.94, P = 0.02).

Univariate analysis showed that the EPO dose (P = 0.001) and the albumin level (P = 0.02) were significant predictors of BNP level.

Adjusted multivariate analysis showed significant interaction between the EPO dose and the albumin level (P = 0.01, P = 0.03 respectively.

In conclusion : the plasma BNP levels were not significantly influenced by ultrafiltration volume or time since last dialysis.

However, the BNP levels may be a useful prognostic parameter for assessing the risk of cardiovascular morbidity and mortality in hemodialysis patients.